#USA #Class Action #Boston #Amitiza #Takeda Pharmaceuticals

Amitiza Class Action Lawsuit Notice

On March 9, 2026, Lowey Dannenberg, P.C. announced the initiation of a class-action lawsuit that may impact third-party payors who purchased or paid for the drug Amitiza and its generic counterparts. This notice is particularly relevant to those involved in healthcare reimbursements for this medication, as it highlights alleged pricing irregularities related to Takeda Pharmaceutical Company and its affiliates.

Background of the Case

The lawsuit has been filed in the District of Massachusetts against Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., and Takeda Pharmaceuticals America, Inc. The central claim states that these companies engaged in tactics designed to prolong their market monopoly on Amitiza (Lubiprostone) by delaying the introduction of generic alternatives. As a result, it is alleged that third-party payors were compelled to pay inflated prices for both the branded and generic forms of this drug for an extended period.

Specific Allegations

Plaintiffs assert that the actions of the defendants not only delayed the availability of generic Amitiza by up to five years, but also forced payors to incur excessive costs during this time. The lawsuit seeks to recover damages for those who have financially suffered due to the inflated pricing practices.

Who Might Be Affected?

The lawsuit defines two main classes of affected individuals:

1. Damages Class: Those who purchased or paid for Amitiza or approved generic versions between October 1, 2016, and March 31, 2024, in specific states, including California, Connecticut, and others listed in the notice.
2. Unjust Enrichment Class: Similar timeframe and locations as above with the addition of some other states where purchases were made under the same conditions.

However, not everyone qualifies for the classes. Exclusions apply to individual consumers, defendants' associates, and others as detailed in the full notice.

Options Available to Class Members

Members of the defined class have several options for action:

• - DO NOTHING: By taking no action, individuals will remain within the class and could be eligible for any benefits arising from a trial or settlement. However, this means that they will also be bound by the court's decision in this case.
• - EXCLUDE YOURSELF: If you opt to exclude yourself from the class, you retain the right to pursue individual legal action against the defendants but will forfeit any potential recoveries from the class action. Requests for exclusion must be submitted by April 10, 2026.

Upcoming Trial Information

The trial is set to begin on April 13, 2026, at the John Joseph Moakley United States Courthouse in Boston, Massachusetts. Any adjustments to the schedule or location of the trial will be communicated on the case's website.

More Information

For further details, individuals can visit www.AmitizaTPPLitigation.com, contact a dedicated helpline, or refer to specific mailing addresses provided in the notice. This resource provides comprehensive information regarding eligibility, next steps, and other frequently asked questions regarding the case.

Legal and Healthcare Implications

This class action highlights significant legal and financial implications for third-party payors in the healthcare sector. It underscores the importance of vigilance in pharmaceutical pricing practices and the potential consequences of monopolistic tactics by large pharmaceutical companies. As more individuals become aware of their rights in such matters, it may pave the way for increased scrutiny and change within the industry.

Keep an eye on developments in this case as they unfold, as they may have lasting repercussions in pharmaceutical marketing and pricing strategies, impacting not just third-party payors but also consumers at large.